Abstract: Some embodiments may include an apparatus usable in a laser system. The apparatus may include at least one optical filter to receive a laser beam or laser light along a first axis, the laser beam or laser light generated by the laser system, wherein the at least one optical filter is configured to reflect one of light having a selected wavelength or a remainder of the laser light along a second axis that is non-parallel with the first axis and pass the other of the light having the selected wavelength or the remainder along a third axis that is parallel to the first axis. Other embodiments may be disclosed and/or claimed.

Abstract: Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.

Abstract: Described are methods of modulating the activation of the TRPV1 ion channel by administering at least one cannabinoid and/or terpene compound.

Abstract: Described are methods of modulating the activation of the TRPV1 ion channel by administering at least one cannabinoid and/or terpene compound.

Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.

Abstract: Provided herein are methods of treating pain using pharmaceutical compositions that comprise an allosteric modulator of TRPV1, optionally in admixture with a TRPV1 ligand. The pharmaceutical composition is substantially free of THC and THCA. Also provided are methods of identifying an allosteric modulator of TRPV1 by analyzing binding to a specific binding pocket in TRPV1 and designing a complex mixture comprising the allosteric modulator for treating pain.

Abstract: Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.

Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.

Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease.

Abstract: Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.

Abstract: Provided herein are terpenoid- and cannabinoid-encapsulating PLGA nanoparticles and pharmaceutical compositions comprising the nanoparticles. Further provided are methods of making and using the terpenoid- and cannabinoid-encapsulating PLGA nanoparticles for therapeutic purposes.

Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease.

Abstract: Described are methods of modulating the activation of the TRPV1 ion channel by administering at least one cannabinoid and/or terpene compound.

Abstract: Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.

Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.

Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease.

Abstract: A rainwater collection and distribution system embodying a rain collector apparatus for collecting rainwater in an easy to transport tank is provided, wherein the apparatus is adapted to direct excessive rainwater as well as relocate and distribute rainwater stored in the tank. The rain collector may form an internal cavity for receiving rainwater. A recessed operative surface along an upper portion of the rain collector may form a plurality of apertures for receiving and communicating the rainwater into the internal cavity. The operative surface may be sloped so that rainwater in excess of the capacity of the internal cavity is directed along the slope to a predetermined location. The rain collector may form a handle and a pour spout, whereby a user may transport the rainwater stored in the internal cavity and pour stored rainwater through the pour spout for a desired reuse activity.

Abstract: An integrated incubation, cultivation and curing system and controls for optimizing, standardizing and enhancing plant-based medical therapies by controlling and regulating plant growth, development and performance at any stage of a plant's development including propagating, growth, flowering, fruit formation or during processes associated with the handling of the culture through multiple automated, enclosed and controlled environmental systems and thereby standardizing the resultant product.

Abstract: A method to optimize and enhance plant growth, development and performance at any stage of its development including sowing, growth, flowering, fruit formation or during many processes associated with the handling of the culture through an automated, enclosed and controlled environment system.

Abstract: An apparatus to optimize and enhance plant growth, development and performance at any stage of its development including sowing, growth, flowering, fruit formation or during many processes associated with the handling of the culture through an automated, enclosed and controlled environment system.